Medtech Insight is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Comments for CardioDynamics NCD

This article was originally published in The Gray Sheet

Executive Summary

Firm finds physician support in the majority of more than 200 comments submitted during the initial comment period, ended March 30, on expanded national coverage for its BioZ impedance cardiography technology. CardioDynamics is seeking coverage for the test's management of all patients with hypertension (1"The Gray Sheet" March 6, 2006, In Brief). The firm notes that results of its CONTROL trial supporting this indication have been published since CMS opened the decision. Robert Streimer, deputy director at CMS' Office of Clinical Standards & Quality until 2004, claims the original limited coverage decision for the technology was pushed through by former California congressman Randy "Duke" Cunningham and recommends either totally withdrawing coverage for BioZ or reducing the product's payment. CMS' proposed coverage decision is due Aug. 28...
Advertisement

Related Content

Advertisement
UsernamePublicRestriction

Register

MT023410

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel